Toggle light / dark theme

Get the latest international news and world events from around the world.

Log in for authorized contributors

New immunotherapy drugs target two evasive cancer-driving proteins

Researchers have shown in mice that designer antibodies can curb the growth of tumors by targeting two of cancer’s most infamous offenders—the proteins RAS and p53, which are mutated in many tumors but have largely defied drug development efforts. If their promise holds up in clinical trials, such drugs could make it possible to unleash the body’s immune system on hard-to-treat cancers including pancreatic and ovarian.

“It’s exciting,” says immunologist Jon Weidanz of the University of Texas, Arlington, who co-founded a company that works on similar immunotherapies, called bispecific antibodies. The new drugs can lock onto a few snippets of p53 or RAS jutting out from a tumor cell’s surface—and then trigger immune cells to attack them. “The therapies have the potential to work when there’s a really low number of the target on cells. That is a big deal,” says Weidanz, who wrote a commentary accompanying the papers.

P53 is a tumor suppressor, and the intact protein helps healthy cells repair DNA—or self-destruct if the damage can’t be fixed. When p53 is turned off in tumors, they can grow unchecked. But targeting p53 with drugs is difficult, because restoring its activity is much harder than inhibiting its activity or turning off its production—more typical drug strategies against misbehaving proteins.

Improved blood test offers less invasive way to detect Alzheimer’s disease

A new study in Nature Aging from Lund University in Sweden shows that improved blood tests for the diagnosis of Alzheimer’s disease can now be used with accuracy similar to that of the cerebrospinal fluid tests that have long been the standard in health care. The blood test has been approved for use in Europe, the U.S. and Japan, among other places. The researchers hope that doctors will now gradually be able to use it more widely—and that, in many cases, patients will be able to avoid the more invasive cerebrospinal fluid test.

These new findings are based on cutoff values that directly reflect clinical practice. The results show that this improved blood test, which has previously received FDA approval and CE marking for clinical use, is just as accurate as the established cerebrospinal fluid test—detecting Alzheimer’s disease pathology with at least 90% accuracy.

It is the first time this has been demonstrated, says Noëlle Warmenhoven, a doctoral student in the Clinical Memory Research Unit at Lund University.

Astronomers discover remarkable triple-star system just 28 light-years from Earth

Astronomers have discovered a stellar system just 28 light-years from Earth that challenges our understanding of how stars live, die and interact as they evolve.

Given the name Welopōʻai, this unusual triple-star system was discovered by an international team of scientists led by the Trottier Institute for Research on Exoplanets (IREx) at Université de Montréal.

They detail their discovery in a study published in Astronomy & Astrophysics.